These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

915 related items for PubMed ID: 9317195

  • 21. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [Abstract] [Full Text] [Related]

  • 22. Mouse models of sickle cell disease.
    Beuzard Y.
    Transfus Clin Biol; 2008 Nov; 15(1-2):7-11. PubMed ID: 18502677
    [Abstract] [Full Text] [Related]

  • 23. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
    Steinberg MH, Voskaridou E, Kutlar A, Loukopoulos D, Koshy M, Ballas SK, Castro O, Barton F.
    Am J Hematol; 2003 Feb; 72(2):121-6. PubMed ID: 12555216
    [Abstract] [Full Text] [Related]

  • 24. New antisickling agents.
    Labie D.
    Haematologia (Budap); 1983 Feb; 16(1-4):105-8. PubMed ID: 6679483
    [Abstract] [Full Text] [Related]

  • 25. Determinants of fetal hemoglobin response to hydroxyurea.
    Steinberg MH.
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):8-14. PubMed ID: 9317196
    [Abstract] [Full Text] [Related]

  • 26. Beta-S gene cluster haplotypes modulate hematologic and hemorheologic expression in sickle cell anemia. Use in predicting clinical severity.
    Powars DR, Meiselman HJ, Fisher TC, Hiti A, Johnson C.
    Am J Pediatr Hematol Oncol; 1994 Feb; 16(1):55-61. PubMed ID: 7508688
    [Abstract] [Full Text] [Related]

  • 27. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
    Rogers ZR.
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):42-7. PubMed ID: 9317200
    [Abstract] [Full Text] [Related]

  • 28. 5-Azacytidine increases fetal hemoglobin production in a patient with sickle cell disease.
    Dover GJ, Charache SH, Boyer SH, Talbot CC, Smith KD.
    Prog Clin Biol Res; 1983 Jul; 134():475-88. PubMed ID: 6198661
    [Abstract] [Full Text] [Related]

  • 29. Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion.
    Conran N, Franco-Penteado CF, Costa FF.
    Hemoglobin; 2009 Jul; 33(1):1-16. PubMed ID: 19205968
    [Abstract] [Full Text] [Related]

  • 30. Intracellular polymerization of sickle hemoglobin. Effects of cell heterogeneity.
    Noguchi CT, Torchia DA, Schechter AN.
    J Clin Invest; 1983 Sep; 72(3):846-52. PubMed ID: 6886006
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Sickle cell disease; a general overview.
    Schnog JB, Duits AJ, Muskiet FA, ten Cate H, Rojer RA, Brandjes DP.
    Neth J Med; 2004 Nov; 62(10):364-74. PubMed ID: 15683091
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Sickle cell disease: role of reactive oxygen and nitrogen metabolites.
    Wood KC, Granger DN.
    Clin Exp Pharmacol Physiol; 2007 Sep; 34(9):926-32. PubMed ID: 17645642
    [Abstract] [Full Text] [Related]

  • 36. [Effect of hydroxyurea on hemoglobin S].
    Torres AF, Eberle SE, Sciuccati G, Bonduel M.
    Medicina (B Aires); 2003 Sep; 63(2):140-2. PubMed ID: 12793083
    [Abstract] [Full Text] [Related]

  • 37. Sickle cell disease caused by Hb S/Québec-CHORI: treatment with hydroxyurea and response.
    Tubman VN, Bennett CM, Luo HY, Chui DH, Heeney MM.
    Pediatr Blood Cancer; 2007 Aug; 49(2):207-10. PubMed ID: 17551985
    [Abstract] [Full Text] [Related]

  • 38. Understanding mechanisms of gamma-globin gene regulation to develop strategies for pharmacological fetal hemoglobin induction.
    Pace BS, Zein S.
    Dev Dyn; 2006 Jul; 235(7):1727-37. PubMed ID: 16607652
    [Abstract] [Full Text] [Related]

  • 39. Hemoglobin S polymerization: primary determinant of the hemolytic and clinical severity of the sickling syndromes.
    Brittenham GM, Schechter AN, Noguchi CT.
    Blood; 1985 Jan; 65(1):183-9. PubMed ID: 3965046
    [Abstract] [Full Text] [Related]

  • 40. New advances in the treatment of sickle cell disease: focus on perioperative significance.
    Dix HM.
    AANA J; 2001 Aug; 69(4):281-6. PubMed ID: 11759366
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 46.